Back to the main directory
EarningsReview / Equity
- Signs of top-line acceleration by BNP Paribas Exane
- Q4/FY21 results and 15 questions for management by BNP Paribas Exane
- OCBC Ltd (OCBC SP) by HSBC
- A product(ivity) of their environment by BNP Paribas Exane
- Nanoform - Scale benefits, now and ahead by Danske Bank Equity Research
- Bakkafrost - Buy/NOK 700: Appealing despite grim results in Scottish lochs by Nordea
- Jyske Bank - Hold: Strong loan growth and lower costs ahead by Nordea
- Norsk Hydro - Hold: Profits set to remain robust by Nordea
- SAS - Sell/SEK 0.50: Essential to succeed with rescue plan by Nordea
- Bakkafrost (Hold, TP: NOK630.00) - Not firing on all cylinders by DnB Markets
- Norsk Hydro (Hold, TP: NOK80.00) - Soft Q4 earnings, aluminium rising by DnB Markets
- Royal Unibrew (Buy, TP: DKK890.00) - Strong end to 2021e by DnB Markets
- Gentian Diagnostics (Buy, TP: NOK92.00) - NT-proBNP set for delay by DnB Markets
- Not sweating it by BNP Paribas Exane
- Motus Holdings Ltd (MTH SJ) by HSBC
- Itaú BBA on CCU: 4Q21 EBITDA Up 23%, but Higher Costs Loom by Itau
- Itaú BBA on Genomma Lab: Stronger-Than-Expected 4Q21 Operating Results by Itau
- Elopak (Hold, TP: NOK29.00) - Weak report and margin guidance by DnB Markets
- Catena (Buy, TP: SEK565.00) - Potential ramp-up in 2022–2023e by DnB Markets
- PhotoCure (Buy, TP: NOK155.00) - Improved outlook in Europe by DnB Markets
- Sustainable food fight III - What''s whet our appetite? by BNP Paribas Exane
- Are we delusional to raise estimates again? by BNP Paribas Exane
- Plant-based digest: European alternative milk trends by BNP Paribas Exane
- Nothing broken by BNP Paribas Exane
- Morgan Sindall (MGNS LN) by HSBC